Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have received a consensus recommendation of “Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $89.64.
A number of equities analysts recently commented on SAGE shares. Leerink Swann reiterated an “outperform” rating and set a $97.00 price target (up previously from $90.00) on shares of Sage Therapeutics in a report on Tuesday, June 20th. ValuEngine upgraded Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Stifel Nicolaus started coverage on Sage Therapeutics in a report on Wednesday. They set a “buy” rating and a $104.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $82.00 price target on shares of Sage Therapeutics in a report on Tuesday, June 13th. Finally, Canaccord Genuity set a $110.00 price objective on Sage Therapeutics and gave the stock a “buy” rating in a report on Saturday, August 5th.
Sage Therapeutics (SAGE) traded up 1.28% on Friday, reaching $84.68. The company’s stock had a trading volume of 252,288 shares. Sage Therapeutics has a 52-week low of $35.02 and a 52-week high of $90.43. The firm has a 50-day moving average price of $81.82 and a 200 day moving average price of $70.17. The firm’s market capitalization is $3.17 billion.
Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by $0.25. During the same period last year, the company posted ($1.08) earnings per share. Equities analysts anticipate that Sage Therapeutics will post ($7.38) earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new stake in Sage Therapeutics during the fourth quarter worth $538,000. State Board of Administration of Florida Retirement System increased its position in shares of Sage Therapeutics by 7.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,056 shares of the biopharmaceutical company’s stock valued at $616,000 after buying an additional 800 shares in the last quarter. Norges Bank purchased a new position in shares of Sage Therapeutics during the fourth quarter valued at approximately $12,452,000. Teachers Advisors LLC increased its position in shares of Sage Therapeutics by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 49,296 shares of the biopharmaceutical company’s stock valued at $2,517,000 after buying an additional 6,419 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Sage Therapeutics by 7,004.1% in the first quarter. Bank of Montreal Can now owns 12,006 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 11,837 shares in the last quarter.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with our FREE daily email newsletter.